NCT05957523 Effects of Remote Ischemic Preconditioning on Peripheral Blood Biomarkers in Healthy Adults (EMINENT)
| NCT ID | NCT05957523 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital Xi'an Jiaotong University |
| Condition | Ischemic Preconditioning |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-06-27 |
| Primary Completion | 2024-10-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-06-27 with a primary completion date of 2024-10-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to investigate the effects of remote ischaemic preconditioning on the peripheral blood characteristics of healthy adults and to explore the possible mechanisms for improving ischaemia/reperfusion injury and its protective effects on the cardiovascular system.
Eligibility Criteria
Inclusion Criteria: * Aged 18 to 45 years; * Be in good health; * Consent to participate in the clinical trial and sign the informed consent form. Exclusion Criteria: * Abnormal results in biochemical checks and physiological indicators. * Cardiovascular and cerebrovascular diseases: hypertension, coronary heart disease, congenital heart disease, cerebrovascular alterations, etc. * Endocrine diseases: diabetes, thyroid disorders, etc. * Hematologic diseases: anemia, paroxysmal hemoglobinuria, primary thrombocytosis, etc. * Infectious diseases: hepatitis B, hepatitis C, syphilis, etc. * Cancer. * Neurological and psychiatric disorders. * Vascular diseases: peripheral vascular disease, Raynaud's syndrome, thromboembolic diseases. * Major trauma or surgery within the last six months. * Pregnant or breastfeeding women. * Upper limbs unsuitable for compression treatment: history of upper limb surgery, presence of tissue damage and limb deformity, and concomitant hemorrhagic diseases. * Recent circumstances that may affect results: blood donors within the last month, any medication taken within the last month, fever within the last week, women within their menstrual cycle or within 7 days before the start of menstruation. * Patients who refuse to sign the informed consent form for participation in this study.
Contact & Investigator
Guoliang Li
PRINCIPAL INVESTIGATOR
First Affiliated Hospital Xi'an Jiaotong University
Frequently Asked Questions
Who can join the NCT05957523 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Ischemic Preconditioning. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05957523 currently recruiting?
Yes, NCT05957523 is actively recruiting participants. Contact the research team at liguoliang_med@163.com for enrollment information.
Where is the NCT05957523 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT05957523 clinical trial?
NCT05957523 is sponsored by First Affiliated Hospital Xi'an Jiaotong University. The principal investigator is Guoliang Li at First Affiliated Hospital Xi'an Jiaotong University. The trial plans to enroll 80 participants.